Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.25+0.14 (+0.87%)
Close on Nov 18, 2026Market cap $3.01BP/E –Yield –
Legend Biotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Legend Biotech's operating income for the twelve months ending Jun 30, 2026 was -$55.18M. For fiscal 2025 it was -$136.50M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$136.50M | – |
| FY2024 | Dec 31, 2024 | -$309.50M | – |
| FY2023 | Dec 31, 2023 | -$528.10M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$49.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$43.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$51.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$79.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$70.36M | – |
See a number that looks wrong?